Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,591.90
(
0.54%
)
US TECH 100
23,454.40
(
0.41%
)
Dow Jones
46,429.49
(
0.66%
)
Brent Oil
98.54
(
-0.24%
)
Bitcoin
71,345.01
(
0.06%
)
News Focus
News Focus
Post# of 257286
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122810
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 225979

Monday, 05/09/2022 11:01:11 AM

Monday, May 09, 2022 11:01:11 AM

Post# of 257286
OXUR.BR -43% on phase-2 failure in DME:

https://finance.yahoo.com/news/oxurion-announces-top-line-results-063000823.html

The Part A data showed THR-687 to be safe and well tolerated with no serious adverse events and none of the patients required rescue medication through Month 3, however, there was insufficient evidence of efficacy on the key endpoints (Best-Corrected Visual Acuity and Central Subfield Thickness). As a result, Oxurion has decided not to advance THR-687 to Part B of the INTEGRAL trial.

In other words, the DME program is kaput. A prior phase-2 trial in the same indication failed in 2019 (#msg-150629948).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today